Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2024 Apr;31(4):342-347.
doi: 10.1111/iju.15368. Epub 2023 Dec 19.

Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: A multicenter observational study

Wataru Fukuokaya  1 , Yuhei Koike  1 , Yuji Yata  1 , Kazumasa Komura  2   3 , Taizo Uchimoto  2 , Takuya Tsujino  2 , Masanobu Saruta  4 , Kiyoshi Takahara  4 , Kazutoshi Fujita  5 , Takafumi Minami  5 , Takahiro Adachi  6 , Yosuke Hirasawa  6 , Takeshi Hashimoto  6 , Yoshio Ohno  6 , Hirotsugu Uemura  5 , Ryoichi Shiroki  4 , Haruhito Azuma  2 , Takahiro Kimura  1
Affiliations
Observational Study

Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: A multicenter observational study

Wataru Fukuokaya et al. Int J Urol. 2024 Apr.

Abstract

Objectives: To explore the characteristics of patients and assess the effectiveness of enfortumab vedotin (EV) in those with treatment-resistant advanced urothelial cancer in a real-world setting.

Patients and methods: A multicenter observational study was conducted on 103 evaluable patients with advanced urothelial cancer who received EV. Outcomes were assessed by radiographic response, progression-free survival (PFS), and overall survival (OS), with treatment-related adverse events (trAEs). Radiographic response was assessed using Response Evaluation Criteria in Solid Tumors version 1.1, while trAEs were studied in line with Common Terminology Criteria for Adverse Events version 5.0.

Results: The median follow-up was 8.9 months (range, 0.1-16.4). The observed objective response rate was 50.5%. The median PFS was 6.0 months (95% CI: 4.7-9.8), and the median OS was 14.5 months (95% CI: 12.4-not reached). Out of the 103 patients, 19 (18.4%) had an Eastern Cooperative Oncology Group performance status of 2 or more, 14 (14.7%) had an non-urothelial carcinoma histology, and 40 (38.3%) had at least one pre-existing comorbidity. There were 26 (25.2%) patients who reported 49 trAEs, with 9 (18.3%) being grade 3 or higher. The most common trAEs included rash, occurring in 18.4%.

Conclusions: This study describes the characteristics and outcomes of patients with previously treated advanced urothelial cancer receiving EV. The findings demonstrate that EV showed robust anti-tumor activity and had manageable safety profiles outside the clinical trial setting.

Keywords: bladder cancer; enfortumab vedotin; renal pelvic cancer; ureter cancer; urothelial carcinoma.

PubMed Disclaimer

References

REFERENCES

    1. von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al. Long‐term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. JCO. 2005;23:4602–4608.
    1. Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, et al. Pembrolizumab as second‐line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376:1015–1026.
    1. Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383:1218–1230.
    1. Dumontet C, Reichert JM, Senter PD, Lambert JM, Beck A. Antibody–drug conjugates come of age in oncology. Nat Rev Drug Discov. 2023;22:641–661.
    1. Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Durán I, Lee JL, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021;384:1125–1135.

Publication types

MeSH terms

LinkOut - more resources